+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cryptococcosis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896168
  • Report
  • January 2020
  • Region: Global
  • 113 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Alkopharma Inc
  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals
  • Novartis AG
  • Pfizer Inc
  • MORE
Market Overview

Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, Hodgkin lymphoma, other lymphomas, sarcoidosis and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection. Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (blood or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia), etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining. According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths.
The growing prevalence of cryptococcosis and the availability of advance treatment are the key factors that drive the growth of the cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.

Scope of the Report

Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. Cryptococcosis therapeutics are segmented by Treatment (Amphotericin B, Flucytosine, Fluconazole, others) and Geography.

Key Market Trends

Flucytosine Segment is Expected to Hold a Significant Market Share in the Cryptococcosis Therapeutics
  • Flucytosine is a small, very water-soluble molecule which is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications.
  • In the year 2016, Flucytosine was a major revenue holding segment because it is given as first-line treatment in combination with other antifungal medications.
  • According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately.
  • Increasing the prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors for the growth of the cryptococcosis market.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major share globally in the cryptococcosis market due to the rising prevalence of cryptococcosis, the rise in technological advancements and the higher cost of medication in this region. In the United States prevalence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. In the year 2015, North America hold a highest market share on the global cryptococcosis market. However, the rising prevalence of cryptococcosis in the endemic areas of the United States is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Cryptococcosis Therapeutics Market is moderately consolidated and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some companies are adopting numerous strategies including acquisitions and collaborations to sustain market competition. Some of the companies which are currently dominating the market are Abbott Laboratories, Alkopharma Inc, Astellas Pharma Inc, Bristol-Myers Squibb Company, Glenmark Pharmaceuticals, Janssen Biotech Inc. (Johnson & Johnson), Novartis AG, Pfizer Inc, Sigmapharm Laboratories LLC, Valeant Pharmaceuticals Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Alkopharma Inc
  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals
  • Novartis AG
  • Pfizer Inc
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Fatal Fungal Disease
4.2.2 Favorable Reimbursement Policies
4.2.3 New and Advanced Treatment Opportunities
4.3 Market Restraints
4.3.1 Adverse Effects of the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Amphotericin B
5.1.2 Flucytosine
5.1.3 Fluconazole
5.1.4 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Alkopharma Inc
6.1.3 Astellas Pharma Inc
6.1.4 Bristol-Myers Squibb Company
6.1.5 Glenmark Pharmaceuticals
6.1.6 Janssen Biotech Inc. (Johnson & Johnson)
6.1.7 Novartis AG
6.1.8 Pfizer Inc
6.1.9 Sigmapharm Laboratories LLC
6.1.10 Valeant Pharmaceuticals Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Alkopharma Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc. (Johnson & Johnson)
  • Novartis AG
  • Pfizer Inc
  • Sigmapharm Laboratories LLC
  • Valeant Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll